Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Five Wound Dressing Categories Should Be Class I, 510(k) Exempt - HIMA

This article was originally published in The Gray Sheet

Executive Summary

The Health Industry Manufacturers Association is proposing that FDA designate five types of unclassified preamendments wound dressings as Class I devices exempt from 510(k) requirements.

You may also be interested in...



Wound dressing downclassification

Nonreabsorbable gauze/sponges for external use, hydrophilic wound dressings, occlusive wound dressings, and hydrogel wound dressings are downclassified to Class I, 510(k)-exempt status in an Oct. 4 final rule. The General and Plastic Surgery Devices Panel recommended the downclassification at a November 1998 meeting. The Health Industry Manufacturers Association had recommended that porcine wound dressings also be Class I, 510(k)-exempt (1"The Gray Sheet" Nov. 16, 1998, p. 8). FDA plans to address porcine wound dressing in the future. Some panel members had raised concerns about the potential risk for the transmission of infectious materials in wound dressings that are composed of materials derived of animal-based sources

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel